PURPOSE: To conduct a Phase I trial to determine the maximally tolerated dose (MTD) of tipifarnib in combination with conventional three-dimensional conformal radiotherapy (RT) for patients with glioblastoma multiforme. METHODS AND MATERIALS: After resection or biopsy, tipifarnib was given 1 week before and then continuously during RT (60 Gy), followed by adjuvant administration until progression. The tipifarnib dose during RT was escalated in cohorts of 3 starting at 200 mg/day. RESULTS: Thirteen patients were enrolled, and 12 were evaluable for MTD. Of these patients, 7 had undergone biopsy, 4 had partial resection, and 1 had gross total resection. No dose-limiting toxicity (DLT) was observed during the concomitant treatment at 200 mg. All 3 patients at 300 mg experienced DLT during the concomitant treatment: 1 with sudden death and 2 with acute pneumonitis. The MTD was reached at 300 mg. The adjuvant treatment was suppressed from the protocol after a case of pneumonitis during this treatment. Six additional patients were included at 200 mg/day of the new protocol, confirming the safety of this treatment. Of the 9 evaluable patients, 1 had partial response, 4 had stable disease, and 3 had rapid progression; the patient with gross total resection was relapse-free after 21 months. Median survival of the evaluable patients was 12 months (range, 5.2-21 months). CONCLUSION: Tipifarnib (200 mg/day) concurrent with standard radiotherapy is well tolerated in patients with glioblastoma. Preliminary efficacy results are encouraging.
PURPOSE: To conduct a Phase I trial to determine the maximally tolerated dose (MTD) of tipifarnib in combination with conventional three-dimensional conformal radiotherapy (RT) for patients with glioblastoma multiforme. METHODS AND MATERIALS: After resection or biopsy, tipifarnib was given 1 week before and then continuously during RT (60 Gy), followed by adjuvant administration until progression. The tipifarnib dose during RT was escalated in cohorts of 3 starting at 200 mg/day. RESULTS: Thirteen patients were enrolled, and 12 were evaluable for MTD. Of these patients, 7 had undergone biopsy, 4 had partial resection, and 1 had gross total resection. No dose-limiting toxicity (DLT) was observed during the concomitant treatment at 200 mg. All 3 patients at 300 mg experienced DLT during the concomitant treatment: 1 with sudden death and 2 with acute pneumonitis. The MTD was reached at 300 mg. The adjuvant treatment was suppressed from the protocol after a case of pneumonitis during this treatment. Six additional patients were included at 200 mg/day of the new protocol, confirming the safety of this treatment. Of the 9 evaluable patients, 1 had partial response, 4 had stable disease, and 3 had rapid progression; the patient with gross total resection was relapse-free after 21 months. Median survival of the evaluable patients was 12 months (range, 5.2-21 months). CONCLUSION:Tipifarnib (200 mg/day) concurrent with standard radiotherapy is well tolerated in patients with glioblastoma. Preliminary efficacy results are encouraging.
Authors: Jiangbing Zhou; Kofi-Buaku Atsina; Benjamin T Himes; Garth W Strohbehn; W Mark Saltzman Journal: Cancer J Date: 2012 Jan-Feb Impact factor: 3.360
Authors: Soléakhéna Ken; Alexandra Deviers; Thomas Filleron; Isabelle Catalaa; Jean-Albert Lotterie; Jonathan Khalifa; Vincent Lubrano; Isabelle Berry; Patrice Péran; Pierre Celsis; Elizabeth Cohen-Jonathan Moyal; Anne Laprie Journal: J Neurooncol Date: 2015-07-19 Impact factor: 4.130
Authors: Phioanh Leia Nghiemphu; Patrick Y Wen; Kathleen R Lamborn; Jan Drappatz; H Ian Robins; Karen Fink; Mark G Malkin; Frank S Lieberman; Lisa M DeAngelis; Alejandro Torres-Trejo; Susan M Chang; Lauren Abrey; Howard A Fine; Alexis Demopoulos; Andrew B Lassman; Santosh Kesari; Minesh P Mehta; Michael D Prados; Timothy F Cloughesy Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-08 Impact factor: 7.038
Authors: Daphne A Haas-Kogan; Anuradha Banerjee; Tina Young Poussaint; Mehmet Kocak; Michael D Prados; J Russell Geyer; Maryam Fouladi; Alberto Broniscer; Jane E Minturn; Ian F Pollack; Roger J Packer; James M Boyett; Larry E Kun Journal: Neuro Oncol Date: 2011-03 Impact factor: 12.300